News
Blog
11.5.2023

Studying vaccines for CMV (cytomegalovirus)

FVR - Finnish Vaccine Research has a team of specialists who have conducted two major clinical studies of CMV vaccines over several years, enrolling healthy women under 40 years of age. Our track-record of enrolling participants for these studies is good, despite screening criteria that limit the number of qualified participants, such as contact with young children, seronegativity or –positivity of the subject, or long commitment to study.

Finland offers an excellent setting for a successful study

  • educated and health-conscious people willing to participate in studies
  • generally a low drop-out rate once participants have committed to a study​
  • extensive network of research clinics
  • high quality register data and solid expertise available for phase 4 Real-World Evidence and pragmatic trials

See Outi Laajalahti, ​Regional Lead Physician, discuss the topic on YouTube >>

Want to speak to an expert?
Your one-stop-shop for all inquiries and feasibilities is: feasibility@fvr.fi. However, if you'd prefer to speak to an expert or have any questions, please get in touch with Arto or Ilona.
Medical & scientific queries
Arto Palmu
Chief Scientific Officer
arto.palmu@fvr.fi
Commercial queries
Ilona Schmidt
Head of Key Accounts
ilona.schmidt@fvr.fi